Greenstreet Yvonne

Yvonne Greenstreet (CEO) sold 2,933 shares for $947,580.95 on 2026-03-04; stock down 34.7% from 52-week high, -30.0% over 90 days.

Greenstreet executed 8 separate sales totaling 2,933 shares for $947,580.95 at blended average price of $323.08, reducing her holdings by 3.0% to 95,695 shares. The sale occurred as the stock trades at $320.66, down 34.7% from its 52-week high of $491.22 and down 30.0% over the past 90 days, despite the company's strong fundamentals showing $1.2B in revenue, 65.2% annual growth, and net income of $251.1M. Prior to this filing, Greenstreet executed 5 sales at ALNY on 2026-03-02 (outcomes not yet measurable), and her broader cross-ticker track record shows 20 prior open-market sells with an average 30-day return of -12.2%. The timing and size of the current multi-tranche sale warrants monitoring given the sharp recent price decline and whether it represents continued liquidation or a one-time adjustment.

CEO Greenstreet sold 6,799 shares for $2.2M at blended $327.65 on 2026-03-02; stock -33.4% from 52-week high, -29.7% in 90 days.

Greenstreet Yvonne, CEO of Alnylam, executed 10 separate sales totaling 6,799 shares for $2,227,698.49 on 2026-03-02 at prices ranging from $323.62 to $331.93 (blended average $327.65). This represents a 6.4% reduction in her holdings from 105,427 to 98,628 shares. The timing context is notable: the stock stands -33.4% from its 52-week high of $491.22 and has declined -29.7% over the past 90 days, even as the company reports strong fundamentals with annual revenue growth of +65.2%, $1.2B in latest-quarter revenue, and $251.1M net income. The CEO's cross-ticker track record shows 20 prior open-market sells with an average 30-day return of -12.1%, though prior timing outcomes at Alnylam (5 previous same-ticker trades) are not yet measurable. The multiple-transaction structure and execution across a narrow price band on a single date do not align with a forced or emergency liquidation pattern, warranting attention to whether this reflects portfolio rebalancing, tax management, or broader confidence signals about valuation.

CEO Yvonne Greenstreet sold 6,958 shares of ALNY at $310.08 for $2,157,542.21; stock down 32.3% from 52-week high.

Greenstreet sold 6,958 shares on 2026-02-13 at $310.08, reducing her stake from 92,620 to 85,662 shares (a -7.5% reduction). The stock has declined 32.3% from its 52-week high of $491.22 and is down 7.4% over 30 days and 27.8% over 90 days. This sale follows a pattern: Greenstreet executed five prior sales at ALNY on 2026-01-12, and across those measurable 30-day windows, post-sale returns averaged -12.4% (ranging from -11.7% to -13.9%), consistent with her cross-ticker track record of -11.5% average 30-day return after sells. Despite strong fundamentals—$1.2B quarterly revenue, +65.2% annual growth, $251.1M net income—the stock's pronounced recent weakness and the CEO's sequential selling pattern merit attention, though no 90-day outcomes on prior ALNY trades are yet measurable to assess timing accuracy.

CEO Greenstreet sells 9,577 shares ($3.5M) across 21 transactions on 2026-01-12; stock down 6.3% in 30 days, 23.7% in 90 days.

Yvonne Greenstreet, CEO of Alnylam, executed 21 separate sales totaling 9,577 shares for $3,475,156.51 on 2026-01-12 at prices ranging from $353.95 to $375.65 per share, reducing her holdings by 10.9%. The current stock price of $366.86 sits 25.3% below the 52-week high of $491.22, and has declined 6.3% over the past 30 days and 23.7% over the past 90 days. Notably, Greenstreet's prior five sales at Alnylam (all on 2025-11-13) each showed 30-day declines of approximately 11.4% to 12.6%, and her cross-ticker track record across 20 prior sells averaged a 30-day return of -12.2%. The company posted strong fundamentals with $1.2B quarterly revenue, +23.0% annual growth, and $251.1M net income, yet carries an unusually elevated P/E of 1111.70, reflecting recent profitability volatility. The timing of this large, multi-tranche sale on a down day—following a pattern of downside outcomes in recent prior trades at this ticker—warrants investor attention to any accompanying scheduled plan disclosures or corporate guidance changes.

CEO Greenstreet sells 25,650 shares for $11.6M over two days at $447.73–$457.71, reducing holdings by 28.2%

Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals, executed 20 separate sales totaling 25,650 shares for $11,613,003.42 across November 12–13, 2025, at prices ranging from $447.73 to $457.71 (blended average $452.75). This represents a -28.2% reduction in her holdings from 91,059 shares to 65,409 shares. The current stock price of $449.16 sits -8.6% from the 52-week high of $491.22 and is down -4.5% over the past 30 days. Her prior ALNY trades from October 2, 2025 (five sales executed within a month prior to this filing) showed mixed near-term outcomes: 30-day returns ranging from -0.4% to +1.8%, with an average of +0.6%. At the cross-ticker level, her track record across all tickers shows 20 prior sells with an average 30-day return of +0.4%, indicating the stock has typically risen modestly after her dispositions. The company reported revenue of $1,249,026,000 with net income of $251,084,000 in the latest quarter, alongside annual revenue growth of +23.0%, but was unprofitable over the full fiscal year, creating tension between strong top-line momentum and profitability headwinds. The sale volume and timing in proximity to recent prior trades merit monitoring, though post-transaction price movement and any disclosed strategic context remain the primary indicators of transaction motivation.

CEO Greenstreet sells 8,924 shares ($4.0M) across 12 transactions on 2025-10-02; holds 65,409 post-sale

Greenstreet Yvonne, CEO of Alnylam Pharmaceuticals, executed 12 separate sales totaling 8,924 shares for $4,034,084.66 on 2025-10-02, reducing her holdings by 12.0% to 65,409 shares. The blended average transaction price of $452.05 sits near the current price of $456.35, with the stock up 2.0% over 30 days and 37.5% over 90 days—indicating strong recent momentum. Alnylam remains unprofitable (net income $-66,277,000.00) despite solid revenue growth of 23.0% year-over-year, suggesting the company is in an investment phase. The multiple separate executions at incrementally rising prices ($446.53 to $457.64) and the proximity of the sale to recent highs ($482.13 at 52-week high) warrant attention to whether this reflects a pre-planned cadence or discretionary reassessment of position size.

CEO Yvonne Greenstreet sold 6,979 shares at blended $453.27 for $3.2M on 2025-08-18; stock now at $458.28

Yvonne Greenstreet, the CEO of Alnylam Pharmaceuticals, executed 8 separate sales totaling 6,979 shares for $3,163,345.74 at prices ranging from $447.98 to $455.82, reducing her holdings by 11.0% from 63,200 shares to 56,221 shares. The transaction occurred near the 52-week high of $458.28, with the stock up 43.0% over the prior 30 days and 56.6% over 90 days. Notably, Greenstreet's prior 5 sales at Alnylam between March and June 2025 were all poorly timed—her 90-day measurable outcomes from March trades showed gains of 25.7% and 23.1%, meaning the stock rose after she sold. Against her cross-ticker track record of a 5.88% well-timed rate (where 50% would represent random timing), this persistent pattern of selling into strength at Alnylam warrants monitoring, particularly given the company remains unprofitable despite 23.0% annual revenue growth and a $60.1B market capitalization.

CEO Yvonne Greenstreet sold 50,937 shares (~51% of holdings) for $15.5M across 3 transactions at blended $305.00

Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, executed 3 separate sales totaling 50,937 shares for $15,535,784.00, reducing her position by 51.0% from 99,885 to 48,948 shares. The transactions occurred at prices ranging from $304.00 to $306.00 near the stock's 52-week high of $306.09, with the stock now trading at $303.77. Notably, Greenstreet's cross-ticker track record shows 20 prior open-market sells with an average 90-day return of +17.0% and a 20.00% well-timed rate, yet her prior trades at ALNY (5 sales, all on 2025-03-03) showed 0 of 5 well-timed at the 90-day mark, with positive returns following each March sale. The company remains unprofitable on a full-year basis despite strong 23.0% annual revenue growth, adding context to the timing near a 52-week high.

CEO Greenstreet sold 3,877 shares for $945,164.88 on 2025-03-03 at blended avg $243.79, retaining 98,635 shares.

CEO Yvonne Greenstreet executed 7 separate sales totaling 3,877 shares for $945,164.88 on March 3, 2025, at prices ranging from $242.37 to $248.36, reducing her holdings by 3.8%. The stock is currently trading at $249.23, down 17.1% from its 52-week high of $300.55 and down 9.2% over the past 30 days. Across her cross-ticker track record, Greenstreet's prior sells have shown a 41.67% well-timed rate at the 90-day mark; however, at ALNY specifically, she completed 5 prior sales on 2025-02-28 with outcomes not yet measurable, making it difficult to assess her timing pattern at this ticker. Against the backdrop of Alnylam's recent price weakness and the company's unprofitable state ($-111.6M net income on $500.9M revenue in the latest quarter), the magnitude and execution style of this sale—multiple tranches across different price levels in a single day—warrants investor attention to what may be motivating the CEO's liquidation activity.

Yvonne Greenstreet, ALNY CEO, sells 2,900 shares for $700,893.68 in 8 transactions on 2025-02-28

Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, executed 8 separate sales totaling 2,900 shares for $700,893.68 on 2025-02-28, reducing her stake from 87,447 to 84,547 shares (-3.3%). The sale occurred at a blended average price of $241.69, near the current price of $243.53, and at a point where the stock is down 19.0% from its 52-week high and down 10.2% over 30 days. While Greenstreet's cross-ticker track record shows a 90-day well-timed rate of 38.46% across 20 prior sells, no timing assessment can be applied to this filing given its structure. The company reported unprofitability with a net income of $-111,570,000.00 over its most recent full fiscal year, though it achieved 23.0% annual revenue growth.